OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.

About

Latest News

GT Biopharma Announces Update to OXS-3550 IND Filing, Its Most Advanced Tri-specific Killer Engager
May 16, 2018 • 8:55 EDT | Read More

Gt Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
May 14, 2018 • 7:45 EDT | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range